STERIS plc
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- STERIS plc (NYSE: STE), headquartered in Dublin, Ireland, with U.S. operational headquarters in Mentor, Ohio, is a leading global provider of infection prevention, contamination control, and procedural support products and services to healthcare, pharmaceutical, medical device, life sciences, and industrial customers in more than 100 countries. Founded in 1985 as Innovative Medical Technologies, the company offers capital equipment including steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, automated washer/disinfectors, surgical tables, lights, booms, operating room integration systems, and automated endoscope reprocessors; consumables such as detergents, disinfectants, endoscopy accessories, barrier products, sterility assurance indicators, biological and chemical monitoring tools, sterilization pouches, and surgical instruments including V. Mueller, Snowden-Pencer, and Genesis brands; and services encompassing equipment installation and maintenance, instrument and scope repair, outsourced reprocessing, laboratory testing, contract sterilization via gamma irradiation, electron beam, ethylene oxide, and X-ray technologies, and gastrointestinal support solutions. STERIS operates through segments including Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies, targeting hospitals, surgery centers, medical device and pharmaceutical manufacturers, research facilities, and bioprocessing clients with a workforce exceeding 18,000 associates. Recent developments include the 2023 acquisition of Becton, Dickinson and Company's surgical instrumentation, laparoscopic, and sterilization container assets to expand healthcare offerings; facility expansions such as the 2025 openings of an ethylene oxide processing plant in Batu Kawan, Malaysia, and an X-ray processing addition in Suzhou, China; a 2024 business segment restructuring; and fiscal 2025 guidance projecting 8-9% revenue growth driven by consumables, services, and bioprocessing demand.
Company News
STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
STERIS to Present at the Morgan Stanley Healthcare Conference
Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?
Should Investors Buy STERIS as Growth Meets Reasonable Valuation?
STERIS Q1 Earnings Call Highlights
STERIS Q1 Earnings Call Highlights
STERIS plc (STE) Q1 2027 Earnings Call Transcript
STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading
5 Quality Stocks Set to Reward Investors With Dividend Hikes
Here's What Key Metrics Tell Us About Steris (STE) Q1 Earnings
Steris (STE) Q1 Earnings Surpass Estimates
STERIS Announces Financial Results for Fiscal 2027 First Quarter
Steris to invest $600 million in new North Carolina chemicals manufacturing hub
STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina
STERIS Raises Dividend to $0.69 per share
STERIS' Q1 Earnings on Deck: What's in Store for the Stock?
STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026
Steris: A Good Moment To Buy Shares In This Sterilization Leader
Entropy Technologies LP Has $2.19 Million Holdings in STERIS plc $STE
STERIS plc $STE Shares Acquired by Arrowstreet Capital Limited Partnership